Dr. Finer has more than 35 years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several first-in-class drugs into the clinic, developing novel technology platforms which integrate science, engineering, and informatics, and building new biotech companies. He is currently a Venturae Partner at Third Rock Ventures where he is involved in founding and launching new therapeutics companies to address unmet medical needs (including Septerna, Maze Therapeutics, and Ambys Medicines). Dr. Finer is also currently CEO at Septerna and has roles on the Boards of Directors of Strateos, Septerna, Ambys, and Maze. Earlier in his career, Dr. Finer spent several years in R&D leadership positions including Interim Chief Technology Officer at Maze Therapeutics, Interim Chief Technology Officer at Ambys Medicines, Vice President of Research Technology at Theravance Biopharma, Vice President, Discovery at Five Prime Therapeutics, and Director, Drug Discovery Technologies at Cytokinetics. Dr. Finer obtained his MD and PhD in Biochemistry from Stanford University School of Medicine, and he holds BS degrees in Chemistry and Biology from the Massachusetts Institute of Technology. He completed residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School.